NCT05204394View on ClinicalTrials.gov

Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

438

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

October 16, 2023

Conditions
HIV-1-infection
Interventions
DRUG

VM-1500A-LAI

Injectable nanoformulation of depulfavirine (parent drug of elsulfavirine)

OTHER

Standard of Care

Any oral 1st line approved HIV treatment regimen

Trial Locations (2)

111123

Federal State Budgetary Institution of the Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow

190103

"St. Petersburg State Medical Institution Center for AIDS and Infectious Diseases", Saint Petersburg

Sponsors

Lead Sponsor

Viriom
All Listed Sponsors
lead

Viriom

INDUSTRY

NCT05204394 - Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy | Biotech Hunter | Biotech Hunter